Claims for Patent: 5,595,978
Summary for Patent: 5,595,978
| Title: | Composition and method for treatment of CMV retinites |
| Abstract: | This invention concerns compositions and methods for the treatment of CMV infections. A composition including an antisense oligonucleotide targeted to the IE2 gene of CMV and a pharmaceutically acceptable carrier were used stop progression in CMV retinitis. |
| Inventor(s): | Kenneth G. Draper, Sharon K. Chapman, Daniel L. Kisner |
| Assignee: | Ionis Pharmaceuticals Inc |
| Application Number: | US08/233,711 |
| Patent Claims: |
1. A method for treating CMV retinitis comprising administering by intravitreal injection an effective amount of a composition comprising SEQ ID NO: 1 and a pharmaceutically acceptable carrier to an animal having CMV retinitis. 2. The method of claim 1 wherein the pharmaceutically acceptable carrier is a buffered solution. 3. The method of claim 1 wherein the animal is a human. 4. A composition comprising SEQ ID NO: 1 and a pharmaceutically acceptable carrier. 5. A composition comprising SEQ ID NO: 1 and a bicarbonate buffered solution. 6. A method for the treatment of CMV retinitis comprising administering an effective amount of a composition of claim 4 intravitreally in combination with ganciclovir to an animal having CMV retinitis. 7. A method for the treatment of CMV retinitis comprising administering an effective amount of a composition of claim 5 intravitreally in combination with ganciclovir to an animal having CMV retinitis. 8. A method for the treatment of CMV retinitis comprising administering an effective amount of a composition of claim 4 intravitreally in combination with foscarnet to an animal having CMV retinitis. 9. A method for the treatment of CMV retinitis comprising administering an effective amount of a composition of claim 5 intravitreally in combination with foscarnet to an animal having CMV retinitis. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch